AUROPHARMA.NSAUROPHARMA.NSNSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +8.53% | +10.58% | +3.98% | +6.28% | +8.36% |
| Gross Profit Growth | +10.99% | +8.71% | +2.99% | -29.34% | -27.30% |
| EBITDA Growth | +6.43% | -0.30% | +3.31% | +14.05% | +22.11% |
| Operating Income Growth | +9.97% | +7.04% | -0.65% | -64.07% | -62.95% |
| Net Income Growth | -9.66% | -0.58% | -10.28% | +3.80% | +7.62% |
| EPS Growth | -9.23% | +0.32% | -9.50% | +4.36% | +7.62% |
| EPS Diluted Growth | -9.23% | +0.32% | -9.50% | +4.36% | +7.62% |
| Weighted Average Shares Growth | -0.48% | -0.90% | -0.86% | -0.52% | -0.02% |
| Weighted Average Shares Diluted Growth | -0.48% | -0.90% | -0.86% | -0.52% | -0.02% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +19.61% | +0.00% | +9.36% | +0.00% |
| Inventory Growth | +0.00% | +7.50% | +0.00% | +7.29% | +0.00% |
| Asset Growth | +0.00% | +10.46% | +0.00% | +9.26% | +0.00% |
| Book Value per Share Growth | +10.07% | +10.41% | +10.32% | +14.08% | +0.00% |
| Debt Growth | +0.00% | +24.30% | +0.00% | -7.51% | +0.00% |
| R&D Expense Growth | +0.00% | +11.14% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +14.33% | +7.61% | +14.63% | +42.18% | +47.79% |